Skip to Content
Merck
All Photos(1)

Key Documents

SBAT07

Sigma-Aldrich

Mdr1b Rat

membrane preparation for ATPase Assays, recombinant, expressed in baculovirus infected Sf9 cells

Synonym(s):

Abcb1b, SB-ratMdr1b-Sf9-ATPase, p-glycoprotein, rodent multidrug resistance protein

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352202
NACRES:
NA.84

recombinant

expressed in baculovirus infected Sf9 cells

form

liquid

concentration

5 mg/mL

color

off-white

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

General description

Membrane Preparations for ATPase Assays are suitable for drug-efflux transporter interaction studies based on ATPase activity determination, and could be used for differentiation between transporter substrates and inhibitors.

Application

The ATPase assay is an in vitro membrane assay designed to indicate the nature of the interaction between the compound and the transporter. By measuring ATPase activity, both activation and inhibition of transporters can be investigated using membranes from baculovirus-infected insect cells or mammalian cell membranes containing high levels of human or rodent wild-type transporters. ABC transporters mediate the transport of substrates against a concentration gradient using energy derived from ATP hydrolysis, which is proportional to the transporter activity and could easily be detected with a colorimetric method.

To assess activation, ABC transporter-rich membranes are incubated with various (typically in 8) concentrations of the test article and the effect on basal ATPase activity is measured. Compounds that stimulate ATPase are generally considered substrates for the transporter. To assess inhibition, a test article′ ability to modify the activity of a given ABC transporter stimulated with its prototypical substrates is examined. The activation and inhibition tests are complementary assays.

Stimulation detected in the activation assay indicate that the compound is a transported substrate of the transporter, while interactions detected in the inhibition test indicate interaction of the test compounds with the transporter, but do not give information on the nature (substrate or inhibitor) of the interaction. In some cases inhibitors or slowly transported compounds may inhibit the baseline transporter ATPase activity as well.

Slowly transported substrates often do not stimulate the ATPase activity in a detectable extent; however the existing interaction can be identified in the inhibition assay.

Physical form

Supplied as frozen membrane vesicles, containing 5 mg/ml membrane protein, labeled with volume, catalog number (transporter) and date of production.

Legal Information

Distributed for SOLVO Biotechnology, Inc.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese.
C G L Lee et al.
Journal of medical genetics, 41(5), e60-e60 (2004-05-04)
Drug-drug interactions of new active substances: mibefradil example.
M Siepmann et al.
European journal of clinical pharmacology, 56(3), 273-273 (2000-08-22)
Siegfried Drescher et al.
British journal of clinical pharmacology, 53(5), 526-534 (2002-05-08)
The C3435T polymorphism in the human MDR1 gene is associated with lower intestinal P-glycoprotein expression, reduced protein function in peripheral blood cells and higher plasma concentrations of the P-glycoprotein substrate digoxin. Using fexofenadine, a known P-glycoprotein substrate, the hypothesis was
Zsuzsanna Rajnai et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(11), 2000-2006 (2010-08-12)
Seliciclib, a cyclin-dependent kinase inhibitor, is a promising candidate to treat a variety of cancers. Pharmacokinetic studies have shown high oral bioavailability but limited brain exposure to the drug. This study shows that seliciclib is a high-affinity substrate of ATP-binding
Ya-tong Zhang et al.
British journal of clinical pharmacology, 66(2), 240-246 (2008-08-23)
Ciclosporin (CsA), which is widely used in autoimmune disease and transplantation, has a narrow therapeutic index. It also shows considerable interindividual variability in its pharmacokinetics, which may be attributable to polymorphisms of the multidrug efflux pump P-glycoprotein, encoded by MDR-1.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service